During this period, medicinal chemistry increasingly integrated mechanistic pharmacology with synthetic innovation. Researchers prioritized enabling technologies for rapid molecule assembly, such as activated ester chemistry, while pursuing targeted enzyme inhibition, which diversified drug classes across neurology, ophthalmology, and cancer. The approach fused SAR-guided design with early safety evaluation, setting the stage for systematic, target-driven drug discovery.